CDX0159-06
95 evidence topics · 19 sources
Objective
Objective stated in the primary publication
Dose-finding purpose stated by the company
Objectives of the Week 52, follow-up, and off-treatment analyses
Location and study date
Number of locations in the ClinicalTrials.gov record
Screening dates, last Week 12 visit, and regions in the primary publication
Sites and countries stated by the company: 9 countries
Sites and countries in the 52-week presentation: 10 countries
First participant dosed, June 2022
Interim data cut for the 52-week analysis
Study design
Design in the ClinicalTrials.gov record
Study periods, randomization ratio, and stratification in the primary publication
Blinding and unblinded pharmacist
Dose selection based on healthy volunteer modeling
Re-randomization at Week 16 and off-treatment follow-up
Clinic visits and diaries in each period
Design stated by the company
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
“Women who are pregnant or nursing.” (opens the source at this quote in a new tab)
“Clearly defined cause for chronic urticaria.” (opens the source at this quote in a new tab)
“Active, pruritic skin condition in addition to CSU.” (opens the source at this quote in a new tab)
“History of anaphylaxis” (opens the source at this quote in a new tab)
“Prior treatment with barzolvolimab” (opens the source at this quote in a new tab)
Eligibility in the primary publication, including antihistamine dose and hematology criteria
Biologic washout and prior omalizumab in the primary publication
Population described in the congress presentations, including prior biologics
Treatment
Arms in the ClinicalTrials.gov record
| Arm | Description |
|---|---|
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
Dosing schedule with placebo injections in the every-8-weeks group
Rescue antihistamine and oral corticosteroids
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Primary endpoint and UAS7 definition in the ClinicalTrials.gov record
Secondary endpoints in the ClinicalTrials.gov record: ISS7, HSS7, and AAS7
Complete response as the treatment goal, and UAS7 disease activity categories
Secondary and exploratory endpoints in the primary publication, including CSU-free status
UAS7 health states used for the Week 52 to Week 76 follow-up
Angioedema Activity Score over 7 days: range and dimensions
AAS7 improvement of more than 8 points as the clinically meaningful threshold
Urticaria Control Test and Dermatology Life Quality Index: ranges and thresholds
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and power in the primary publication
Planned enrollment stated at the first dose, June 2022
Actual enrollment in the ClinicalTrials.gov record
Participants screened, randomized, treated, and completing Week 12
Participants per randomized group in the primary publication
Participants treated and entering the 24-week follow-up period
Participants in the post hoc off-treatment analysis
Participants in the angioedema subgroup
Participants in the pigmentation analysis
Participants in the baseline IgE subgroup analysis
Description of analysis sets
Modified intent-to-treat and safety populations
Handling of missing daily diary scores
Week 12 primary analysis: analysis of covariance with multiple imputation and Benjamini-Hochberg adjustment
Congress presentations: modified intent to treat and as-observed analyses
Pooled dose groups in the safety tables of the congress presentation
Post hoc subgroup analyses by baseline IgE and baseline serum tryptase
Results
Participant disposition
Disposition through Week 12
Treatment discontinuations through Week 52 by randomized group
| Reason | 75 mg every 4 weeks, then 150 or 300 mg | 150 mg every 4 weeks | 300 mg every 8 weeks | Placebo, then 150 or 300 mg |
|---|---|---|---|---|
| Group size | “(n=53)” | “(n=52)” | “(n=52)” | “(n=51)” |
| Discontinued treatment, n (%) | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |
| Patient decision | “1 (2%)” | “3 (6%)” | “1 (2%)” | “3 (6%)” |
| Non-compliance | “2 (4%)” | “1 (2%)” | “1 (2%)” | “2 (4%)” |
| Lack of clinical response | “1 (2%)” | “0” | “2 (4%)” | “1 (2%)” |
| Other | “2 (4%)” | “5 (10%)” | “2 (4%)” | “0” |
Discontinuations during the 16-week placebo-controlled period and adverse events leading to discontinuation
Participants treated and entering the follow-up period
Baseline characteristics
Demographics and baseline disease characteristics by randomized group
Baseline imbalances in the 300 mg every 8 weeks group
Baseline AAS7 in participants with angioedema at baseline
Baseline UCT and DLQI in the 150 mg and 300 mg groups
Baseline characteristics of participants with well-controlled disease at Week 52
Efficacy results
Week 12 primary endpoint: UAS7 change from baseline versus placebo
Week 12 efficacy endpoints by randomized group
| Endpoint at Week 12 | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Placebo (n = 51) |
|---|---|---|---|---|
| UAS7 LS mean change from baseline (SE) | “−17.06 (1.493)” | “−23.02 (1.416)” | “−23.87 (1.479)” | “−10.47 (1.462)” |
| UAS7 treatment difference vs placebo (95% CI) | “−6.60 (−10.71, −2.49)” | “−12.55 (−16.56, −8.55)” | “−13.41 (−17.47, −9.34)” | Not applicable |
| ISS7 LS mean change from baseline (SE) | “−8.62 (0.794)” | “−11.68 (0.766)” | “−11.79 (0.788)” | “−5.47 (0.784)” |
| ISS7 treatment difference vs placebo (95% CI) | “−3.16 (−5.41, −0.91)” | “−6.21 (−8.38, −4.04)” | “−6.32 (−8.50, −4.13)” | Not applicable |
| HSS7 LS mean change from baseline (SE) | “−8.25 (0.747)” | “−11.19 (0.750)” | “−12.19 (0.745)” | “−4.95 (0.772)” |
| HSS7 treatment difference vs placebo (95% CI) | “−3.31 (−5.40, −1.22)” | “−6.24 (−8.33, −4.16)” | “−7.24 (−9.36, −5.12)” | Not applicable |
| AAS7 LS mean change from baseline (SE) | “−24.10 (2.831)” | “−27.99 (2.815)” | “−29.95 (2.843)” | “−12.56 (3.056)” |
| AAS7 treatment difference vs placebo (95% CI) | “−11.55 (−20.04, −3.05)” | “−15.43 (−23.52, −7.34)” | “−17.39 (−25.49, −9.30)” | Not applicable |
| Well-controlled disease (UAS7 ≤ 6) (%) | “41.7” | “59.6” | “62.5” | “12.8” |
| UAS7 ≤ 6 difference in proportions vs placebo (95% CI) | “0.29 (0.12, 0.46)” | “0.47 (0.3, 0.64)” | “0.50 (0.33, 0.66)” | Not applicable |
| Complete control (UAS7 = 0) (%) | “22.9” | “51.1” | “37.5” | “6.4” |
| UAS7 = 0 difference in proportions vs placebo (95% CI) | “0.17 (0.03, 0.3)” | “0.45 (0.29, 0.61)” | “0.31 (0.16, 0.46)” | Not applicable |
| CSU-free status (ISS7 = 0, HSS7 = 0, and AAS7 = 0) (%) | “19.2” | “50.0” | “33.3” | “5.9” |
Week 12 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) versus placebo
Week 12 angioedema activity (AAS7) in participants with angioedema at baseline
Week 12 AAS7 improvement of more than 8 points and angioedema-free days
| Measure at Week 12 (participants with angioedema at baseline) | 300 mg every 8 weeks | 150 mg every 4 weeks | 75 mg every 4 weeks | Placebo |
|---|---|---|---|---|
| Angioedema at baseline, n (%) | “42 (82%)” | “35 (67%)” | “40 (75%)” | “32 (63%)” |
| Baseline AAS7 (mean) | “53.15” | “54.60” | “54.05” | “56.30” |
| >8 point improvement in AAS7 (%) | “85.0” | “87.1” | “82.9” | “57.1” |
| Angioedema free days (mean) | “65.1” | “54.5” | “43.3” | “36.2” |
Week 12 serum tryptase reduction
Week 52 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) after re-randomization at Week 16
Week 52 response stated by the company and by prior omalizumab experience
Week 52 angioedema activity (AAS7) in participants with angioedema at baseline
Week 52 and Week 76 AAS7 change and angioedema-free status (AAS7 = 0) across the four groups
Week 12 and Week 52 efficacy by baseline IgE
Week 12 and Week 52 efficacy by baseline serum tryptase
Week 76, 28 weeks after the last dose: UAS7 change, UAS7 = 0, and UAS7 ≤ 6
“UAS7 Mean CFB (SE) at W76” (opens the source at this quote in a new tab)
“150 mg Q4W was -20.4 (2.5)” (opens the source at this quote in a new tab)
“300 mg Q8W was -21.1 (1.9)” (opens the source at this quote in a new tab)
“UAS7=0 (%) at W76” (opens the source at this quote in a new tab)
“150 mg Q4W was 41%” (opens the source at this quote in a new tab)
“300 mg Q8W was 35%” (opens the source at this quote in a new tab)
“UAS7≤6 (%) at W76” (opens the source at this quote in a new tab)
“150 mg Q4W was 56%” (opens the source at this quote in a new tab)
“300 mg Q8W was 47%” (opens the source at this quote in a new tab)
“Modified intent to treat; observed data.” (opens the source at this quote in a new tab)
Week 76 in participants with well-controlled disease (UAS7 ≤ 6) at Week 52
Week 76 disease severity at recurrence after treatment completion
Health-related quality of life and patient-reported outcomes
Week 12 Urticaria Control Test (UCT7): treatment differences versus placebo
Well-controlled urticaria (UCT7 ≥ 12) at 12 and 52 weeks and 28 weeks after the last dose
Week 52 UCT and DLQI change from baseline in the 150 mg and 300 mg groups
Week 52 DLQI 0 or 1, DLQI improvement, and UCT control stated by the company
Week 76 DLQI 0 or 1
Week 76 DLQI in participants with well-controlled disease (UAS7 ≤ 6) at Week 52
Week 52 and Week 76 DLQI in the post hoc quality of life analysis
Safety results
Baseline through Week 12: adverse events, serious adverse events, and discontinuations
| Event | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Pooled barzolvolimab (n = 156) | Placebo (n = 51) |
|---|---|---|---|---|---|
| Patients with ≥1 TEAE | “28 (52.8)” | “29 (55.8)” | “31 (60.8)” | “88 (56.4)” | “14 (27.5)” |
| Patients with serious AE | “0” | “0” | “1 (2.0)” | “1 (0.6)” | “0” |
| Discontinued study treatment due to TEAE | “2 (3.8)” | “1 (1.9)” | “4 (7.8)” | “7 (4.5)” | “0” |
| Hair color changes | “0” | “5 (9.6)” | “9 (17.6)” | “14 (9.0)” | “0” |
| Urticaria/CSU | “8 (15.1)” | “5 (9.6)” | “3 (5.9)” | “16 (10.3)” | “5 (9.8)” |
| Neutropenia (neutropenia and neutrophil count decreased) | “4 (7.6)” | “3 (5.7)” | “5 (9.8)” | “12 (7.7)” | “0” |
Week 12 neutropenia: onset, duration, and infections
Week 16 placebo-controlled period and Week 52 full treatment period: adverse events
| Patients, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 (N= 156) | Placebo, Weeks 0 to 16 (N= 51) | Barzolvolimab, all doses, Weeks 0 to 52 (N= 156) | Placebo then barzolvolimab, 36 weeks (N=48) |
|---|---|---|---|---|
| At least one AE | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment related SAEs | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia / neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |
“Placebo Controlled Period (16 weeks)” (opens the source at this quote in a new tab)
“Full Treatment Period (52 weeks)” (opens the source at this quote in a new tab)
“4 SAEs of worsening urticaria symptoms” (opens the source at this quote in a new tab)
“Adverse events were not dose dependent” (opens the source at this quote in a new tab)
Week 52 neutrophil counts and skin hypopigmentation stated by the company
Follow-up period through 76 weeks: neutrophil recovery and reversibility of pigment changes
Hair color and skin pigmentation changes over 76 weeks: incidence, onset, severity, and resolution
Limitations of the pigmentation photography stated by the authors
Study limitations
Summary
- Sample size: the study was sized at 168 participants (42 per group) for 80% power to detect a UAS7 difference of at least 9 points at week 12. Of 208 participants randomized, 207 were in the mITT and safety populations. Approximately 20% (n=41) had prior omalizumab, and the authors state of the omalizumab-refractory subgroup that “the number of patients in this subgroup was small”.
- Duration of placebo control: the placebo-controlled treatment phase ran from baseline to week 16. At Week 16 the placebo and 75 mg groups were re-randomized 1:1 to 150 mg Q4W or 300 mg Q8W for 36 weeks, so every group received barzolvolimab from Week 16 to Week 52.
- Peer-reviewed scope: the primary publication reports the primary analysis, conducted when all participants completed week 12. Week 52 results are from a congress presentation based on an interim data cut of July 31, 2024, and Week 76 results are from congress presentations and the Form 10-Q.
- Multiplicity: the publication states “P values are nominal; only the primary end point P values were adjusted for multiplicity.”
- Missing data: the week 12 primary analysis used analysis of covariance with multiple imputation, while the Week 76 and angioedema congress analyses are labeled modified intent to treat with observed data or as-observed. Overall, 189 participants (91.3%) completed 12 weeks of treatment. Through 52 weeks, 13 (25%) participants in each of the three barzolvolimab groups and 8 (16%) in the placebo-then-barzolvolimab group discontinued treatment, including 7 (13%), 4 (8%), 7 (13%), and 2 (4%) for adverse events.
- Off-treatment and post hoc analyses: the last dose was at Week 48, followed by a 24-week off-treatment follow-up from Week 52 to Week 76. The off-treatment efficacy analysis was post hoc and limited to participants randomized to 150 mg Q4W or 300 mg Q8W who completed 52 weeks with UAS7 ≤ 6 at Week 52 (n = 55), of whom 48 had a reported UAS7 at Week 76. The baseline serum tryptase analyses were exploratory and post hoc.
- Baseline imbalance: the 300 mg group had more participants with higher body weights, more with severe CSU (UAS7 ≥ 28), and a higher percentage with angioedema (82%) than the lower-dose groups and the placebo group.
- Regimens: the phase 2 groups received 150 mg every 4 weeks or 300 mg every 8 weeks for 52 weeks, with placebo injections at the intervening visits of the every-8-weeks group; the phase 3 regimens follow a 300 mg or 450 mg loading dose.
- Counts that differ across documents: the study is described as conducted across 9 countries (Form 10-Q), at ~75 sites in 10 countries (52-week presentation), and at 56 locations (registry); the 300 mg every 8 weeks group is n = 51 in the primary publication and n=52 in the 52-week presentation.
- Immunogenicity: no antidrug antibody results from this study were found.
- Pigmentation analysis: the authors state “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes” and that images were obtained from a subset of participants.